Company: TELO
Filing Date: 2025-02-04
Form Type: 10-K
Source: 0001493152-25-004872
Chunk: 507

Company: Telomir Pharmaceuticals, Inc.
Filing Date: 2025-02-04
Form: 10-K
Item: Item 1A
Chunk 507
---
QUITY 

    Current liabilities: 

    Trade accounts payable
    and accrued liabilities 
    $587,536  
    $707,187 
  
    Due to related parties 
     93,432  
     527,377 
  
    Related
    party line of credit 
     -  
     101,000 
  
    Total current liabilities 
     680,968  
     1,335,564 

    Total liabilities 
     680,968  
     1,335,564 

    Stockholders’ Equity 

    Preferred Stock, no par
    value, 100,000,000 shares authorized and none issued or outstanding. 
     -  
     - 
  
    Common Stock, no par value;
    300,000,000 shares authorized, 29,762,671 and 28,609,814 shares issued and outstanding at December 31, 2024 and December 31, 2023,
    respectively. 
     -  
     - 
  
    Additional paid-in capital 
     31,239,895  
     17,502,346 
  
    Accumulated
    deficit 
     (30,596,858) 
     (14,064,142)
  
    Total
    stockholders’ equity 
     643,037  
     3,438,204 
  
    Total
    liabilities and stockholders’ equity 
    $1,324,005  
    $4,773,768 

The
accompanying notes to the financial statements are an integral part of these statements.

F-3

Telomir
Pharmaceuticals, Inc.

STATEMENTS
OF OPERATIONS

    2024  
    2023 

    Year
    Ended December 31, 

    2024  
    2023 
  
    Revenues 
    $-  
    $- 

    Operating costs: 

    General and
    administrative expenses 
     9,636,333  
     600,192 
  
    Related party travel costs 
     370,500  
     1,767,550 
  
    Research
    and development expenses 
     2,235,341  
     1,574,306 
  
    Total
    operating costs 
     12,242,174